An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Oct 2018
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms ZACTIMA 58; ZETA
- Sponsors AstraZeneca; Sanofi Genzyme
- 31 Aug 2018 Biomarkers information updated
- 02 Dec 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
- 05 Jan 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History